Overview

MK-677 (ibutamoren) is a potent, orally active, non-peptide GHS-R1a (ghrelin receptor) agonist that mimics ghrelin to stimulate pulsatile growth hormone secretion and sustained IGF-1 elevation. Unlike injectable GH secretagogue peptides, MK-677 is orally bioavailable with a half-life of approximately 24 hours, enabling once-daily dosing. It has been investigated in clinical trials for GH deficiency, muscle wasting (HIV/AIDS, surgery recovery), osteoporosis, and as a potential anti-aging agent. It increases GH pulse amplitude without significantly altering pulse frequency.

Mechanism of Action

MK-677 binds and activates GHS-R1a (the ghrelin receptor) on somatotroph cells of the anterior pituitary and hypothalamic neurons expressing ghrelin receptors. This activates Gq/11-coupled phospholipase C, producing IP3 and DAG, raising intracellular calcium and stimulating GH secretion. Additionally, GHS-R1a activation in the hypothalamus increases GHRH release and reduces somatostatin tone, creating a dual mechanism that amplifies both the frequency and amplitude of GH pulses. Sustained GH elevation drives hepatic IGF-1 synthesis via JAK2/STAT5 signaling.

Potential Benefits

  • 24-hour oral dosing convenience vs. injectable GH secretagogues
  • Increased GH pulse amplitude and sustained IGF-1 elevation
  • Lean mass preservation in catabolic states (surgery, HIV wasting)
  • Bone density improvement via IGF-1 signaling
  • Improved sleep quality (specifically slow-wave sleep increase)
  • Potential anti-aging effects via GH/IGF-1 axis restoration

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range10-25 mg/day orally
Beginner10 mg/day at bedtime
Intermediate15-20 mg/day at bedtime
Advanced25 mg/day
Cycle Duration3-6 months; some use year-round at lower doses
Cycle Off1-2 months; 10 mg/day maintenance sometimes used continuously

MK-677 is a non-peptide GH secretagogue taken orally. Half-life ~24 hours allows once-daily dosing. Bedtime dosing aligns GH pulse with natural nocturnal release. Significant appetite stimulation and possible insulin resistance at higher doses.

Routes of Administration

Oral Moderate

~60-80% bioavailability; convenient once-daily oral dosing; consistent plasma levels with daily use; food does not significantly affect absorption

Stacking Protocols

Popular research stacks involving MK-677 (Ibutamoren):

GH Axis Stack (Oral-Friendly)

Enhanced GH/IGF-1 elevation combining injectable GHRH with oral GHS mimetic

MK-677 provides oral GHS activity while CJC-1295 amplifies the GHRH component; suitable for users who prefer to minimize injections.

Mass Building Stack

Maximized anabolic environment through GH and IGF-1 pathway activation

MK-677 elevates endogenous GH/IGF-1 while exogenous IGF-1 LR3 bypasses the GH receptor step for direct tissue growth signaling.

Recovery and Anti-Aging Stack

GH optimization, tissue repair, and longevity support

Practical stack for older adults seeking accessible GH support with added healing and anti-aging peptides.

Reconstitution

Typical Vial SizeN/A — available as oral capsules/tablets (10mg, 25mg)
BAC WaterN/A — oral formulation
StorageStore capsules/powder at room temperature 15-25°C; protect from moisture
Shelf Life24-36 months sealed; 6-12 months after opening

Need exact syringe measurements?

Amino Acid Sequence

N/A (non-peptide small molecule GHS-R1a agonist)

Side Effects & Safety

  • Increased appetite (ghrelin mimetic effect)
  • Water retention and edema
  • Elevated fasting insulin/glucose (monitor in pre-diabetics)
  • Fatigue and lethargy at higher doses
  • Potential worsening of insulin resistance with long-term use

Synergistic Compounds

The following compounds have been studied alongside MK-677 (Ibutamoren) for potential complementary or synergistic effects:

Learn More

References & Further Reading

  • [object Object]
  • [object Object]